- evERA study met co-primary endpoints in ER-positive breast cancer.
- Giredestrant plus everolimus showed significant benefit over standard care.
- No new safety signals were observed in the trial.
- Data to be presented at an upcoming medical meeting.
Study Overview
The phase III evERA study evaluated the combination of giredestrant and everolimus in patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer. These patients had previously been treated with a CDK 4/6 inhibitor and endocrine therapy.
Key Findings
The study successfully met its co-primary endpoints, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for both the intention-to-treat and ESR1-mutated populations compared to standard-of-care endocrine therapy plus everolimus.
Safety Profile
The combination of giredestrant and everolimus was well tolerated, with adverse events aligning with the known safety profiles of the individual treatments. No new safety signals were identified during the trial.
Future Steps
While overall survival data remain immature, a positive trend was noted, and follow-up will continue for the next analysis. The trial's results will be presented at an upcoming medical meeting and shared with health authorities.
